Imigran

Sumatriptan, the active ingredient in Imigran, is a Triptan (5‑HT1B/1D receptor agonist) presented as an oral formulation for systemic use. It is employed to treat acute migraine attacks and related headache disorders in adult patients by inducing cranial vasoconstriction and inhibiting trigeminal pain pathways.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable sourcing for migraine therapies. The company ensures compliance with Good Distribution Practice, supports regulatory documentation, and offers flexible shipping options to meet global demand.

Sumatriptan is indicated for acute treatment of migraine and related headache disorders by targeting serotonergic pathways.

- Migraine (with or without aura): rapid relief of headache pain and associated symptoms during an acute attack. - Cluster headache: alleviates severe unilateral head pain and associated autonomic symptoms in acute episodes. - Acute episodic migraine: reduces the duration and severity of migraine attacks when taken at onset.

Sumatriptan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in fingers or face - Dizziness or light‑headedness - Nausea or abdominal pain - Fatigue or drowsiness - Dry mouth

Serious or Rare Side Effects: - Coronary artery spasm or myocardial infarction - Severe hypertension - Serotonin syndrome, especially with serotonergic drugs - Anaphylactic or severe allergic reactions - Stroke or transient ischemic attack - Severe skin reactions such as Stevens‑Johnson syndrome

When prescribing Sumatriptan, clinicians should evaluate patient history and follow safety guidelines to minimize risks. - Cardiovascular assessment: review history of coronary artery disease, angina, or uncontrolled hypertension before use. - Concomitant serotonergic agents: avoid co‑administration with MAO inhibitors or other serotonergic drugs to reduce serotonin syndrome risk. - Hemiplegic or basilar migraine: contraindicated in patients with these migraine subtypes. - Pregnancy and lactation: use only if potential benefit justifies potential risk; discuss with obstetric provider. - Driving and operating machinery: advise patients to avoid such activities if they experience dizziness or fatigue. - Store at ambient temperature: keep tablets in original container, protect from moisture and heat.

Sumatriptan can interact with several medication classes, influencing efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Other triptans or ergotamine derivatives: additive vasoconstrictive effects may cause cardiovascular events. - SSRIs, SNRIs, or other serotonergic agents: increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Beta‑blockers (e.g., propranolol): may increase plasma levels of sumatriptan. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise sumatriptan concentrations. - Antihypertensive agents: monitor blood pressure as sumatriptan may affect vascular tone.